Immunotherapy

iStock-1160744392

Our portfolio of novel immunotherapy studies translates Birmingham-led science from our Institute of Immunology and Immunotherapy and Institute of Cancer and Genomic Sciences. Recent activity includes:

  • ANICCA-Class II - led by Professor Gary Middleton, this single arm Phase II study assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer, seeking to introduce a new immunotherapeutic stratifier.
  • GOTHAM (Clinical Trials Register): a phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours. Led by Birmingham CI Dr Francis Mussai, it translates research into Myeloid Derived Suppressor Cell (MDSC) biology by Dr MussaiProfessor Gary Middleton and Dr Carmela De SantoGOTHAM is being delivered across the ECMC adult and paediatric network. 

  • MATINS: a phase I/II study assessing Repeated Doses of CLEVER-1 Antibody FP-1305 in patients with advanced solid tumours. This novel commercial study is examining whether inhibiting Clever-1 is key to increasing patient responsiveness to cancer immunotherapy. It translates laboratory work by Birmingham CRUK Advanced Clinical Scientist Dr Shishir Shetty.

We have a growing portfolio of advanced therapy studies, in both haematological and solid cancers, and benefit from close collaboration with the Midlands and Wales Advanced Therapy Treatment Centre. We are drawing on their expertise and learning resources to develop our staff competencies and ensure that we deliver these complex studies effectively.

Theme Lead: Dr Francesca Kinsella, an NIHR Clinical Lecturer in Experimental Haematology, with research interests in Graft Versus Host Disease and cellular therapies.